
## Luciana Kase Tanno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8729872/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Allergy in the World Health Organization's International Classification of Diseases (ICD)â€11. Pediatric Allergy and Immunology, 2022, 33, 5-7.	1.1	5
2	Allergic and hypersensitivity conditions in nonâ€specialist care: Flow diagrams to support clinical practice. Allergy: European Journal of Allergy and Clinical Immunology, 2022, , .	2.7	4
3	Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement. World Allergy Organization Journal, 2022, 15, 100640.	1.6	18
4	Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1396-1399.e2.	2.0	3
5	A Proposal from the Montpellier World Health Organization Collaborating Centre for Better Management and Prevention of Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 676-683.e1.	2.0	11
6	Anaphylaxie. , 2021, , 134-144.		0
7	Biologicals for the prevention of anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 303-308.	1.1	7
8	Epidemiology of anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 168-174.	1.1	11
9	Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic. World Allergy Organization Journal, 2021, 14, 100515.	1.6	7
10	Consensus on DEfinition of Food Allergy SEverity (DEFASE) an integrated mixed methods systematic review. World Allergy Organization Journal, 2021, 14, 100503.	1.6	33
11	Utility of drug provocation tests in the evaluation of quinolone hypersensitivity reactions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2097-2100.e2.	2.0	2
12	SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center. Vaccines, 2021, 9, 560.	2.1	10
13	Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship?. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 411-417.	1.1	5
14	Foodâ€induced anaphylaxis morbidity: Emergency department and hospitalization data support preventive strategies. Pediatric Allergy and Immunology, 2021, 32, 1730-1742.	1.1	6
15	Anaphylaxis and Pregnancy: A Systematic Review and Call for Public Health Actions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4270-4278.	2.0	10
16	Anaphylaxis and COVID-19 vaccines: Real-time interest using Google Trends. World Allergy Organization Journal, 2021, 14, 100570.	1.6	2
17	Épidémiologie des maladies allergiques. , 2021, , 12-17.		0
18	Physician's experience on managing asthma in adolescents: results of the International AMADO (Asthma Management in ADOlescents) survey. Asia Pacific Allergy, 2021, 11, e45.	0.6	1

#	Article	IF	CITATIONS
19	Action Plan to Ensure Global Availability of Adrenaline Autoinjectors. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 77-85.	0.6	19
20	The EAACIâ€AAAAIâ€WAO Junior Members' joint survey: A worldwide snapshot of Allergy and Clinical Immunology specialty. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 588-595.	2.7	3
21	Foodâ€induced anaphylaxis in infancy compared to preschool age: A retrospective analysis. Clinical and Experimental Allergy, 2020, 50, 74-81.	1.4	58
22	Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMAâ€compliant systematic review—An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1069-1098.	2.7	16
23	Biologic Agents for the Treatment of Anaphylaxis. Immunology and Allergy Clinics of North America, 2020, 40, 625-633.	0.7	6
24	World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organization Journal, 2020, 13, 100472.	1.6	461
25	Anaphylaxis in children. Pediatric Allergy and Immunology, 2020, 31, 8-10.	1.1	10
26	Self-injectable epinephrine: doctors' attitude and patients' adherence in real-life. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 474-481.	1.1	0
27	Coronavirus Disease (COVID)-19: World Health Organization Definitions and Coding to Support the Allergy Community and Health Professionals. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2144-2148.	2.0	18
28	COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organization Journal, 2020, 13, 100126.	1.6	90
29	Global implementation of the world health organization's International Classification of Diseases (ICD)â€11: The allergic and hypersensitivity conditions model. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2206-2218.	2.7	25
30	Measles epidemiological profile in Brasil from 2013 to 2018. Revista Da Associação Médica Brasileira, 2020, 66, 607-614.	0.3	1
31	Safety and effectiveness of laparoscopic Y-en-Roux gastric bypass surgery in obese elderly patients. Acta Cirurgica Brasileira, 2020, 35, e202000606.	0.3	1
32	Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases–11. Journal of Allergy and Clinical Immunology, 2019, 144, 627-633.	1.5	46
33	Gaps in the management of foodâ€induced anaphylaxis reactions at school. Pediatric Allergy and Immunology, 2019, 30, 767-770.	1.1	22
34	Shared Genetic Risk Factors Across Carbamazepineâ€Induced Hypersensitivity Reactions. Clinical Pharmacology and Therapeutics, 2019, 106, 1028-1036.	2.3	52
35	Time to revisit the definition and clinical criteria for anaphylaxis?. World Allergy Organization Journal, 2019, 12, 100066.	1.6	137
36	Are outcome measures in allergic diseases relevant for the WHO's International Classification of Diseases in allergology?. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 198-203.	1.1	3

#	Article	IF	CITATIONS
37	Asthma and anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 447-455.	1.1	21
38	Therapeutic approach of anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 393-401.	1.1	27
39	Controversies in drug allergy: Testing for delayed reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 66-73.	1.5	144
40	Epidemiological Data on Anaphylaxis in French Emergency Departments. Journal of Investigational Allergology and Clinical Immunology, 2019, 29, 357-364.	0.6	13
41	Foodâ€related anaphylaxis fatalities: Analysis of the Allergy Vigilance Network <sup>®</sup> database. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1193-1196.	2.7	60
42	Use of dupilumab on the treatment of moderate-to-severe asthma: a systematic review. Revista Da Associação Médica Brasileira, 2019, 65, 1223-1228.	0.3	4
43	Ephedrineâ€induced erythrodermia: Clinical diagnostic procedure and crossâ€sensitivity. Contact Dermatitis, 2018, 79, 43-44.	0.8	6
44	Lessons of Drug Allergy Management Through the World Health Organization's International Classification of Diseases (ICD)-11. Current Treatment Options in Allergy, 2018, 5, 52-59.	0.9	2
45	Proactive multi-modality treatment of Pancreatic Neuroendocrine Tumours (PNETs): Potential survival benefits. Pancreatology, 2018, 18, 304-312.	0.5	4
46	Critical view of anaphylaxis epidemiology: open questions and new perspectives. Allergy, Asthma and Clinical Immunology, 2018, 14, 12.	0.9	59
47	EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to nonâ€steroidal antiâ€inflammatory drugs (NSAIDs) in children and adolescents. Pediatric Allergy and Immunology, 2018, 29, 469-480.	1.1	85
48	Fatal anaphylaxis in children in France: Analysis of national data. Pediatric Allergy and Immunology, 2018, 29, 101-104.	1.1	26
49	What can we learn in drug allergy management from World Health Organization's international classifications?. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 987-992.	2.7	30
50	Foodâ€induced fatal anaphylaxis: From epidemiological data to general prevention strategies. Clinical and Experimental Allergy, 2018, 48, 1584-1593.	1.4	120
51	Globalization and anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 365-369.	1.1	11
52	How can the World Health Organization's International Classification of Diseases (ICD)-11 change the clinical management of anaphylaxis?. Expert Review of Clinical Immunology, 2018, 14, 783-786.	1.3	6
53	Management of chronic spontaneous urticaria: a worldwide perspective. World Allergy Organization Journal, 2018, 11, 14.	1.6	28
54	Fatal anaphylaxis registries data support changes in the who anaphylaxis mortality coding rules. Orphanet Journal of Rare Diseases, 2017, 12, 8.	1.2	33

#	Article	IF	CITATIONS
55	Increasing the Accuracy of Notification of Anaphylaxis Deaths in Brazil through the International Classification of Diseases (ICD)-11 Revision. Journal of Allergy and Clinical Immunology, 2017, 139, AB226.	1.5	1
56	Fieldâ€testing the new anaphylaxis' classification for the WHO International Classification of Diseasesâ€11 revision. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 820-826.	2.7	29
57	Perspectives on the International Classification of Diseases, 11th Revision, developments in allergy clinical practice in the United States. Annals of Allergy, Asthma and Immunology, 2017, 118, 127-132.	0.5	10
58	Applying prevention concepts to anaphylaxis: A call for worldwide availability of adrenaline autoâ€injectors. Clinical and Experimental Allergy, 2017, 47, 1108-1114.	1.4	32
59	Validation of the <scp>MASK</scp> â€rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clinical and Experimental Allergy, 2017, 47, 1526-1533.	1.4	75
60	One voice for anaphylaxis in France: The vision of the centre of reference in rare diseases. Revue Francaise D'allergologie, 2017, 57, 583-587.	0.1	2
61	Implementation gaps for asthma prevention and control. Respiratory Medicine, 2017, 130, 13-19.	1.3	18
62	Anaphylaxis in France: Rate, characteristics and unmet needs. Revue Francaise D'allergologie, 2017, 57, 519-524.	0.1	1
63	Reaching multidisciplinary consensus on classification of anaphylaxis for the eleventh revision of the World Health Organization's (WHO) International Classification of Diseases (ICD-11). Orphanet Journal of Rare Diseases, 2017, 12, 53.	1.2	22
64	Collaboration between specialties for respiratory allergies in the International Classification of Diseases (ICD)-11. Respiratory Research, 2017, 18, 34.	1.4	6
65	In-flight allergic emergencies. World Allergy Organization Journal, 2017, 10, 15.	1.6	24
66	Decreasing the undernotification of anaphylaxis deaths in Brazil through the International Classification of Diseases (ICD)-11 revision. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 120-125.	2.7	41
67	A call to arms of specialty societies to review the WHO International Classification of Diseases, Eleventh Revision terms appropriate for the diseases they manage: The example of the Joint Allergy Academies. Allergy and Asthma Proceedings, 2017, 38, 54-55.	1.0	12
68	How to manage anaphylaxis in primary care. Clinical and Translational Allergy, 2017, 7, 45.	1.4	38
69	New Allergic and Hypersensitivity Conditions Section in the International Classification of Diseases-11. Allergy, Asthma and Immunology Research, 2016, 8, 383.	1.1	47
70	Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11. Asia Pacific Allergy, 2016, 6, 149-156.	0.6	29
71	Surveying the new Allergic and hypersensitivity conditions chapter of the International Classification of Diseases ( <scp>ICD</scp> )â€11. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1235-1240.	2.7	26
72	Mast Cell Clonal Disorders: Classification, Diagnosis and Management. Current Treatment Options in Allergy, 2016, 3, 453-464.	0.9	21

#	Article	IF	CITATIONS
73	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clinical and Translational Allergy, 2016, 6, 41.	1.4	24
74	Updating Allergy and/or Hypersensitivity Diagnostic Procedures in the WHO ICD-11 Revision. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 650-657.	2.0	32
75	Smoothing the transition from International Classification of Diseases, Tenth Revision, Clinical Modification to International Classification of Diseases, Eleventh Revision. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1265-1267.	2.0	18
76	Genetic variants associated with drugs-induced immediate hypersensitivity reactions: a PRISMA-compliant systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 443-462.	2.7	39
77	Dissemination of definitions and concepts of allergic and hypersensitivity conditions. World Allergy Organization Journal, 2016, 9, 24.	1.6	43
78	International survey on skin patch test procedures, attitudes and interpretation. World Allergy Organization Journal, 2016, 9, 8.	1.6	15
79	Optimization and simplification of the Allergic and Hypersensitivity conditions classification for the ICD-11. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 671-676.	2.7	34
80	Revisiting Desensitization and Allergen Immunotherapy Concepts for the International Classification of Diseases (ICD)-11. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 643-649.	2.0	25
81	Alergia a anestésicos locales y generales y a otros medicamentos durante procedimientos quirAºrgicos. Revista Universitas Medica, 2016, 51, 392-407.	0.0	Ο
82	Mapping hypersensitivity/allergic diseases in the International Classification of Diseases (ICD)â€11: crossâ€linking terms and unmet needs. Clinical and Translational Allergy, 2015, 5, 20.	1.4	43
83	Making allergic and hypersensitivity conditions visible in the International Classification of Diseases-11. Asia Pacific Allergy, 2015, 5, 193-196.	0.6	28
84	Allergological work-up in the suspicion of drug hypersensitivity in patients undergoing allergen-specific immunotherapy. World Allergy Organization Journal, 2015, 8, A72.	1.6	0
85	Constructing a classification of hypersensitivity/allergic diseases for ICD-11 by crowdsourcing the allergist community. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 609-615.	2.7	57
86	2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organization Journal, 2015, 8, 32.	1.6	422
87	The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects. PLoS ONE, 2015, 10, e0136141.	1.1	11
88	Global classification and coding of hypersensitivity diseases – An EAACI – WAO survey, strategic paper and review. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 559-570.	2.7	62
89	Categorization of allergic disorders in the new World Health Organization International Classification of Diseases. Clinical and Translational Allergy, 2014, 4, 42.	1.4	54
90	Polymorfism Of CYP2C9 And 3A5 and carbamazepine hypersensitivity reactions in Brazilian subjects. Clinical and Translational Allergy, 2014, 4, P49.	1.4	0

#	Article	IF	CITATIONS
91	Polymorfism Of CYP2C9 And 3A5 and carbamazepine hypersensitivity reactions in Brazilian subjects. Clinical and Translational Allergy, 2014, 4, P118.	1.4	Ο
92	Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. World Allergy Organization Journal, 2013, 6, 18.	1.6	55
93	Undernotification of anaphylaxis deaths in <scp>B</scp> razil due to difficult coding under the <scp>ICD</scp> â€10. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 783-789.	2.7	107
94	Respiratory exercise program for elderly individuals with asthma. Clinics, 2011, 66, 1165-1169.	0.6	20
95	Outcomes and safety of drug provocation tests. Allergy and Asthma Proceedings, 2011, 32, 301-306.	1.0	26
96	Epileptic seizure after treatment with thiocolchicoside. Therapeutics and Clinical Risk Management, 2009, 5, 635.	0.9	10
97	Ketoconazole Allergy. Clinics, 2009, 64, 373-374.	0.6	3